Navigation Links
Karolinska Institutet to Test Vical's Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
Date:8/19/2008

SAN DIEGO, Aug. 19 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today announced a research collaboration with the Karolinska Institutet (KI), a leading European medical university, and the Swedish Institute for Infectious Disease Control (SMI), a governmental expert agency, to evaluate Vical's Vaxfectin(R) adjuvant with the Biojector(R) 2000 needle-free injection system (Bioject Medical Technologies Inc., OTCBB: BJCT) for a multivalent preventive DNA vaccine against HIV.

Professor Eric Sandstrom, M.D., Ph.D., Professor at the Karolinska Institutet, said, "The results from our initial Phase 1 trial were quite good, with over 90 percent of subjects achieving detectable immune responses against HIV after the prime-boost vaccination. We hope to improve the breadth and magnitude of immune responses in the next clinical trial by using the Vaxfectin(R) adjuvant with our DNA priming vaccine. We believe that continued development of HIV vaccines remains among the world's top healthcare priorities."

The Karolinska Institutet has completed a 38-subject Phase 1 trial testing a prime-boost HIV vaccine regimen using three doses of unadjuvanted DNA vaccines over a three-month period followed by a single dose of a viral vector vaccine at nine months. The Karolinska Institutet is currently conducting nonclinical safety studies to support a planned Phase 1 trial of a Vaxfectin(R)-formulated HIV DNA vaccine as part of a prime-boost regimen. The Vaxfectin(R) adjuvant is intended to optimize the priming of immune responses and increase the performance of, or potentially even eliminate the need for, the viral vector vaccine boost. The SMI is sponsoring the development.

About the Vaccine

The SMI/KI vaccines contain syn
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Karolinska Institute to Test Vicals Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
2. Nventa Develops Proprietary Vaccine Adjuvant
3. Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients
4. Iomai Receives HHS Approval to Begin Phase 2 Trial of H5N1 Influenza Adjuvant Patch
5. Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant
6. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
7. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
8. U.S. Preventive Medicine: Employers Can Help Workers Avoid Heart Attacks
9. Inhaled Steriods Used as Preventive Treatment Post 9/11
10. U.S. Preventive Medicine Acquires Specialty Disease Management
11. Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)....C., Nov. 6 Chimerix, Inc., a biop...ntiviral therapeutics to address life-threatening ...the company,s lead antiviral compound, CMX001, to ... Health Security Initiative (GHSI). CMX001 is a b...the treatment of smallpox, as well as other seriou...
(Date:11/6/2009)...re-FirstCall/ -- Caraco Pharmaceutical Laboratorie...tromethamine ophthalmic solution, 0.5% following a...ration (FDA) for Sun Pharma,s Abbreviated New Drug...lmic solution on the first day following patent ex...cally equivalent to Acular® Ophthalmic Soluti...
(Date:11/5/2009)...swire/ -- Althea Technologies, Inc., a leading pro...r biopharmaceutical products announced the additio...pany,s platform of services, which will be oversee...tor of Formulation Development. This investment in... scientists, along with new laboratory facilities ...
Breaking Medicine Technology:Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox 2Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox 3Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution 2Althea Technologies Adds Formulation Development to Its Integrated Offering of Contract Services 2RiversEdge BioVentures LLC to Provide Advisory and Investment Services in Life Sciences 13993 1RiversEdge BioVentures LLC to Provide Advisory and Investment Services in Life Sciences 13993 2GENova to acquire three new drug target patents worth in excess of 241 billion in royalty fees 56862 1GENova to acquire three new drug target patents worth in excess of 241 billion in royalty fees 56862 2GENova to acquire three new drug target patents worth in excess of 241 billion in royalty fees 56862 3Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid 56858 1Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid 56858 2Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid 56858 3Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid 56858 4
...l Therapeutics (CTI),(Nasdaq and MTA: CTIC) announ...nd Drug Administration (FDA), CTI expects to begin...) and request priority review for pixantrone to tr...L) in the first quarter of 2009.,If granted priori... the end of,2009. , "This communication from t...
...t Angiolix has similar efficacy to Avastin alone a...th potentially less side-effects; study validates ...DALLAS, Jan. 26 ACCESS PHARMACEUTICALS, INC. (OTC...k on its proprietary humanized monoclonal antibody... with high affinity to the its target, lactadherin...
Other Medicine Technology:Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission 2Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission 3Access Pharmaceuticals Presents new Combination Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody 2Access Pharmaceuticals Presents new Combination Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody 3
(Date:11/8/2009)...SNewswire/ -- The American Public Health Associati...visions in the health reform bill passed last nigh...the House takes important steps toward universal c...d moving our health system from one that focuses o... people healthy," said Georges C. Benjamin, MD, FA...
(Date:11/8/2009)...es self-assurance, research finds , , SU...ave been right when she told you to sit up straigh...ake you feel more confident about your thoughts. ...ght gives a good impression to other people," Rich... professor at Ohio State University, said in a uni...
(Date:11/8/2009)...e game later, doctors say , , SUNDAY, No...k of the NFL this season, sidelining such stars as...arker. , Officials at the American Podiatric Me...c Sports Medicine are warning athletes to take car...otball and lacrosse. , "Many fall sports athlet...
(Date:11/8/2009)...ewswire/ -- Speaker Nancy Pelosi and Democratic le...passage of H.R. 3962, the Affordable Health Care f...to 215. Below are the Speaker,s opening remarks: ...a call from the President of the United States, Ba...or the American people. I thank the President for ...
(Date:11/8/2009)...d "Preventing and Healing AIDS Through Our In...at AIDS is a result of multiple, repeated and chro...em stressor agents, which can be either chemical, ... , Oakland, CA (PRWEB) No...l biologists, physicians, chemists and other scien...
Breaking Medicine News(10 mins):Health News:APHA Applauds Prevention and Wellness Provisions in House Health Reform Bill 2Health News:Good Posture May Inspire Confidence 2Health News:Rx for Fall Foot Injuries 2Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 2Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 3
...ty researchers have identified the role of a key e... the way for new target therapies to reduce plaque...predict a patients susceptibility to heart disease...plaques. , Heart disease results from the format...
...s for respiratory health , , WEDNESDAY, Oc...ngs, a couple of drinks a day may help keep the do...le evidence has mounted that a daily dose of alcoh... the possible protective effect of alcohol involvi...
...ompany Becomes First to Leverage Zagat,s, Expertis...de Feedback and Rate Experiences Using Zag...W YORK, Oct. 24 WellPoint, Inc., the,nation,s lar... their physician experiences with others. A first ...
...ydrate, a novel,medical humidifier, was awarded a ... October 18, 2007. PARI Innovative Manufacturers, ...rs, developed the PARI Hydrate to,revolutionize th...The award, selected by an independent panel of jud...
...ced in healthy volunteers, according to a study by...Diego (UCSD) Center for Medical Cannabis Research ...may be more. , In the placebo controlled study of...results suggest a "therapeutic window" for cannabi...
... the,leading cause of death in the United States, ...izophrenia. The November 2007 issue of the Harvard...great for people with,schizophrenia and what can t... They are also less,likely to receive good prevent...
Other Medicine News:Health News:Role of a key enzyme in reducing heart disease identified 2Health News:Drink or Two a Day May Help Lungs 2Health News:Drink or Two a Day May Help Lungs 3Health News:Drink or Two a Day May Help Lungs 4Health News:WellPoint Taps Zagat Survey to Help Consumers Rate Experiences with Their Doctors 2Health News:WellPoint Taps Zagat Survey to Help Consumers Rate Experiences with Their Doctors 3Health News:PARI's Hydrate Wins Prestigious R&D 100 Award 2Health News:Smoked cannabis proven effective in treating neuropathic pain 2Health News:People with Schizophrenia More Likely to Die of Heart Disease, Reports the Harvard Mental Health Letter 2
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
Medicine Products: